A phase III, multicentre, prospective, randomized double-blind study comparing intraocular pressure lowering efficacy of preservative-free fixed and non-fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with pseudoexfoliative glaucoma (XFG).
Phase of Trial: Phase III
Latest Information Update: 13 Oct 2015
At a glance
- Drugs Tafluprost/timolol (Primary) ; Tafluprost; Timolol
- Indications Glaucoma
- Focus Therapeutic Use
- 13 Oct 2015 New trial record